A Bacterial Lifestyle Switch Provides Antibiotic Resistance
|
By LabMedica International staff writers Posted on 06 Jan 2016 |

Image: Light micrograph of Bacillus cereus in a small colony variant (SCV) (Photo courtesy of Markus Kranzler/Vetmeduni Vienna).
Researchers have reported for the first time that following contact with certain antibiotics the pathogenic Bacillus cereus can switch into a special slowed-down mode and form small colony variants (SVCs) that are difficult to diagnose and almost impossible to treat with certain antibiotics.
Bacillus cereus causes vomiting and diarrhea as well as systemic and local infections such as sepsis or eye infections. The newly discovered mechanism, from a study led by researchers from the Vetmeduni Vienna (University of Veterinary Medicine Vienna (Austria), provides an explanation for this and possibly other cases of antibiotic resistance.
B. cereus had so far been considered to be exclusively endospore-forming in response to harsh conditions. The new study discovered an alternative lifestyle in which B. cereus forms SCVs in response to exposure to aminoglycoside antibiotics. The B. cereus SCVs grow slower, have an altered metabolism, and provide resistance to aminoglycosides. “The bacterium protects itself against the harmful effects of the antibiotics by forming these SCVs. But B. cereus is usually treated with exactly those antibiotics which induce the SCV state. If an antibiotic triggers the formation of SCVs, it also triggers resistance,” explained first author Dr. Frenzel.
The discovery of this mechanism is of great significance for clinical practice and will require rethinking diagnostics and therapy. Traditional diagnostics are based on identification of metabolic features of B. cereus, but these tests do not detect SCVs. This may result in incorrect antibiotic therapies or even failed diagnoses. Molecular tests may be the only way to diagnose this form of B. cereus. Treating B. cereus infections using only aminoglycoside antibiotics could bear the risk of a prolonged infection. SCVs grow more slowly, but they still produce toxins that are harmful to the body. “In this case, a combination therapy with other antibiotic groups is advisable,” Dr. Frenzel recommends.
Another bacterium, Staphylococcus aureus, also forms SCVs, but is capable of reverting to its original state. For B. cereus, the SCV form appears to be final, suggesting a new mechanism. “We believe that the SCV formation in B. cereus functions differently than in S. aureus,” said coauthor Dr. Ehling-Schulz.
“The ability to form SCVs appears to be of environmental significance for the bacteria,” said Dr. Frenzel, “B. cereus are soil-dwelling, and other microorganism in the soil produce antibiotics. Here, too, the formation of SCVs would be an advantage for the bacteria.”
The study, by Frenzel E, Kranzler M et al., was published December 8, 2015, in the journal mBio.
Related Links:
University of Veterinary Medicine Vienna
Bacillus cereus causes vomiting and diarrhea as well as systemic and local infections such as sepsis or eye infections. The newly discovered mechanism, from a study led by researchers from the Vetmeduni Vienna (University of Veterinary Medicine Vienna (Austria), provides an explanation for this and possibly other cases of antibiotic resistance.
B. cereus had so far been considered to be exclusively endospore-forming in response to harsh conditions. The new study discovered an alternative lifestyle in which B. cereus forms SCVs in response to exposure to aminoglycoside antibiotics. The B. cereus SCVs grow slower, have an altered metabolism, and provide resistance to aminoglycosides. “The bacterium protects itself against the harmful effects of the antibiotics by forming these SCVs. But B. cereus is usually treated with exactly those antibiotics which induce the SCV state. If an antibiotic triggers the formation of SCVs, it also triggers resistance,” explained first author Dr. Frenzel.
The discovery of this mechanism is of great significance for clinical practice and will require rethinking diagnostics and therapy. Traditional diagnostics are based on identification of metabolic features of B. cereus, but these tests do not detect SCVs. This may result in incorrect antibiotic therapies or even failed diagnoses. Molecular tests may be the only way to diagnose this form of B. cereus. Treating B. cereus infections using only aminoglycoside antibiotics could bear the risk of a prolonged infection. SCVs grow more slowly, but they still produce toxins that are harmful to the body. “In this case, a combination therapy with other antibiotic groups is advisable,” Dr. Frenzel recommends.
Another bacterium, Staphylococcus aureus, also forms SCVs, but is capable of reverting to its original state. For B. cereus, the SCV form appears to be final, suggesting a new mechanism. “We believe that the SCV formation in B. cereus functions differently than in S. aureus,” said coauthor Dr. Ehling-Schulz.
“The ability to form SCVs appears to be of environmental significance for the bacteria,” said Dr. Frenzel, “B. cereus are soil-dwelling, and other microorganism in the soil produce antibiotics. Here, too, the formation of SCVs would be an advantage for the bacteria.”
The study, by Frenzel E, Kranzler M et al., was published December 8, 2015, in the journal mBio.
Related Links:
University of Veterinary Medicine Vienna
Latest Microbiology News
- FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection
- Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps
- Proteomic Workflow Maps Microbial and Host Responses in Intestinal Inflammation
- Metagenomic Sequencing Enables Faster Diagnosis of Respiratory Infections in Cystic Fibrosis
- Portable Molecular Platform to Advance Point-of-Care Testing for Lassa Fever
- New Sensitive Blood Assay Detects Tuberculosis Antigen Directly in Blood
- Study Highlights Need for Routine Hepatitis E Testing in Cirrhosis
- High-Throughput Automated Platform to Advance Latent Tuberculosis Testing
- Expanded Diagnostics and Therapies Target Rising Gonorrhea Resistance
- New Rapid Ebola Antigen Test Detects Infection at Point of Care
- Syndromic GI Panel Detects Cyclospora for Rapid Case Confirmation
- Rapid Panel Identifies Gram-Negative Pathogens and Resistance Markers in Bloodstream Infections
- Bacterial Growth Assay Predicts COVID-19 Severity From Plasma
- Gut Microbiome Analysis Identifies Frailty-Related Signatures in Older Adults
- CE-Marked Blood Assay Automates Tuberculosis Infection Testing
- Genomic Surveillance Algorithm Improves Early Detection of Emerging Variants
Channels
Clinical Chemistry
view channel
Compact Prenatal Screening System Expands Access to Preeclampsia Testing
Preeclampsia affects an estimated 2%–8% of pregnancies and is rising globally with increasing maternal age, diabetes, and hypertension. While international guidelines recommend screening, access often... Read more
Blood Test on a Chip Offers Low-Cost Lung Cancer Detection Without DNA Sequencing
Lung cancer is the leading cause of cancer deaths worldwide, and screening often yields indeterminate results that prompt invasive workups. Computed tomography (CT) detects small nodules but can flag benign... Read moreMolecular Diagnostics
view channelLiquid Biopsy Combines Multiple Signals for Cancer Detection in a Single Analysis
Detecting and monitoring cancer often requires repeated tissue biopsies, which are invasive and not always feasible. Liquid biopsy offers a less invasive way to track disease over time, but many assays... Read more
Newborn Screening Program Adds Spinal Muscular Atrophy Testing Across England
Spinal muscular atrophy is a rare but serious genetic condition that can rapidly impair motor function in infants and, in severe cases, compromise breathing and swallowing. Detecting the disorder before... Read more
Whole-Cell Genomic Analysis Expands the Potential of Liquid Biopsy
Liquid biopsy has expanded access to tumor genomics, but most blood-based assays rely on short, degraded fragments of cell-free circulating tumor DNA (ctDNA). Isolating intact circulating tumor cells from... Read more
Blood Test Could Help Fast-Track Lymphoma Diagnosis in Resource-Limited Settings
Lymphoma can be difficult to distinguish from infections and benign conditions, while definitive diagnosis often depends on surgical tissue sampling and specialized pathology that may not be readily available.... Read moreHematology
view channel
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read moreImmunology
view channel
Immune Cell Blood Test May Predict Melanoma Immunotherapy Response
Melanoma remains one of the deadliest skin cancers, although outcomes improve markedly when the disease is detected early. Immunotherapy has extended survival for many patients with advanced melanoma,... Read more
Study Reveals Viral Protein Driving COVID-19-Related Vascular Injury
Lingering symptoms after acute COVID-19 infection remain a clinical challenge, with many patients experiencing fatigue, cognitive problems, and cardiovascular complications months later.... Read more
Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read morePathology
view channel
FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis
Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read moreTechnology
view channel
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read more
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Standardized Staining Technology Advances Digital Pathology Workflows
Digital pathology is increasingly used to streamline cancer diagnostics, yet staining variability can hinder slide interpretation and limit the reliability of artificial intelligence tools.... Read more
Global Testing Service Advances Leukemia MRD Monitoring
KMT2A rearrangements drive aggressive subsets of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and are associated with relapse and poor outcomes. As menin inhibitors enter clinical... Read more







